← Back to Clinical Trials
Recruiting NCT05818774

NCT05818774 End-on Versus Parallel Radiofrequency Lesioning for Neurotomy of the Cervical Medial Branch Nerves

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05818774
Status Recruiting
Phase
Sponsor University Health Network, Toronto
Condition Neck Pain
Study Type INTERVENTIONAL
Enrollment 72 participants
Start Date 2023-03-10
Primary Completion 2027-12

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 85 Years
Study Type INTERVENTIONAL
Interventions
Radiofrequency neurotomy (RFN) of Cervical Medial Branch Nerves (CMBNn) with parallel lesioningRadiofrequency neurotomy (RFN) of Cervical Medial Branch Nerves (CMBNn) with end-on lesioning with multitined trident cannulae

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 72 participants in total. It began in 2023-03-10 with a primary completion date of 2027-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Aim of the EndPaRL study is to compare the efficacy and effectiveness of the two techniques utilizing sharp straight conventional radiofrequency needle with a trident needle for radiofrequency neurotomy of Cervical Medial Branch Nerves (CMBNs), in patients presenting with chronic, moderate-to-severe, neck pain due to cervical zygapophyseal joint osteoarthritis, as diagnosed by positive responses to two consecutive diagnostic blocks with local anesthetic of the CMBN.

Eligibility Criteria

Inclusion Criteria: 1. Adult patient of either gender aged 18-85 years 2. Predominant axial (non-radicular) neck pain for at least 3 months 3. 7-day average NRS score for neck pain ≥ 5/10 at baseline evaluation 4. Moderate or greater functional impairment due to pain, defined as NDI Questionnaire raw score of 15 out of 50 (≥30% )e Failure to respond to conservative medical management (pharmacologic, physical therapy) for at least 3 months; f) Positive response to two consecutive diagnostic blocks of the CMBN with a short and long-acting anesthetic Exclusion Criteria: 1. Participants with financial incentives or litigation associated with ongoing pain 2. Inability to complete assessment instruments 3. Chronic widespread pain 4. Prior RFN of the CMBN; 5. Severe mental health issues 6. Pregnancy or other reason that precludes the use of fluoroscopy 7. Untreated coagulopathy 8. Systemic or local infection at the time of screening.

Contact & Investigator

Central Contact

Danielle Alvares, PhD

✉ danielle.alvares@uhn.ca

📞 (416) 603-5800

Principal Investigator

Anuj Bhatia, MD, PhD

PRINCIPAL INVESTIGATOR

Department of Anesthesia and Pain Management, University Health Network, Toronto

Frequently Asked Questions

Who can join the NCT05818774 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 85 Years, studying Neck Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05818774 currently recruiting?

Yes, NCT05818774 is actively recruiting participants. Contact the research team at danielle.alvares@uhn.ca for enrollment information.

Where is the NCT05818774 trial being conducted?

This trial is being conducted at Toronto, Canada, Toronto, Canada, Barcelona, Spain.

Who is sponsoring the NCT05818774 clinical trial?

NCT05818774 is sponsored by University Health Network, Toronto. The principal investigator is Anuj Bhatia, MD, PhD at Department of Anesthesia and Pain Management, University Health Network, Toronto. The trial plans to enroll 72 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology